South San Francisco Biotech Snags Monster $1.9 Billion Cancer Drug Pact With Novartis
Antares Therapeutics has struck a partnership with Novartis that could be worth about $1.9 billion, bringing fresh funding to its South San Francisco and Boston teams.
Duke Lab's One-Shot Gene Therapy Revives Weak Hearts In Early Tests
Duke researchers say a catheter‑delivered gene therapy restored pumping power and cut arrhythmias in lab‑grown heart tissue and monkeys, suggesting a possible one‑shot treatment for heart‑attack damage.
Oregon AI Upstart Rapta Plants Flag In Orlando With New Regional HQ
Oregon‑based Rapta has established a regional headquarters in Orlando to serve aerospace, defense and space manufacturers across the Eastern United States. The move ties the AI firm closer to the Space Coast and local industry partners.
Northwestern Lab Drives Vision Pro Wheelchair Breakthrough in Chicago
Northwestern's Project DRIVE provided software Apple used to let Vision Pro wearers steer powered wheelchairs with their eyes. The feature rolls out initially with limited drive‑system support.
UCLA’s Tiny Tumor ‘Farm’ Lets AI Speed-Test Cancer Drugs
UCLA published a step‑by‑step protocol and open code for an AI‑assisted platform that tracks drug responses in thousands of bioprinted tumor organoids. The methods aim to speed functional testing and move personalized therapy screening closer to clinical use.
South San Francisco Biotech Giant Dragged Into Nationwide Xolair Kickback Showdown
A whistleblower suit unsealed this week alleges decades of kickbacks and false government claims tied to Xolair, naming Genentech, Novartis and other drugmakers.
Menlo Park Money Machine Drops $3 Billion AI Bomb On Silicon Valley
Menlo Ventures marked its 50th anniversary by announcing $3 billion across two AI funds aimed at seed‑to‑growth startups. The raise expands the firm’s bets in infrastructure, healthcare and enterprise AI.












